| abstract |
The present invention discloses 2α-methyl-19-nor vitamin D analogs, specifically 2α-methyl-19-nor-1α-hydroxy-homopregnacalciferol, and pharmaceutical uses thereof. Since this compound inhibits the proliferation of undifferentiated cells and induces differentiation into monocytes, it exhibits remarkable activity as an anticancer agent and skin diseases such as psoriasis, wrinkles, sagging skin, dry skin And uses for the treatment of skin conditions such as insufficient sebum secretion. Furthermore, since the present compound has extremely low, if any, calcemia activity, it can be used for the treatment of human autoimmune disorders or inflammatory diseases, as well as renal bone dystrophy. The present compounds can further be used for the treatment or prevention of obesity. [Selection] Figure 1 |